CoChat

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Abstract

Background IMspire150 aimed to evaluate first-line combination treatment with BRAF plus MEK inhibitors and immune checkpoint therapy in BRAF V600 mutation-positive advanced or metastatic melanoma.Methods IMspire150 was a randomised, double-blind, placebo-controlled phase 3 study done at 112 institutes in 20 countries. Patients with unresectable stage IIIc-IV, BRAF V600 mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group). In cycle 1, all patients received vemurafenib and cobimetinib only; atezolizumab placebo was added from cycle 2 onward. Randomisation was stratified by lactate dehydrogenase concentration and geographical region. Blinding for atezolizumab was achieved by means of an identical intravenous placebo, and blinding for vemurafenib was achieved by means of a placebo tablet. The primary outcome was investigator-assessed progression-free survival. This trial (ClinicalTrials.gov, NCT02908672) is ongoing but no longer recruiting patients.Findings Between Jan 13, 2017, and April 26, 2018, 777 patients were screened and 514 were enrolled and randomly assigned to the atezolizumab group (n=256) or control group (n=258). At a median follow-up of 18·9 months (IQR 10·4-23·8), progression-free survival as assessed by the study investigator was significantly prolonged with atezolizumab versus control (15·1 vs 10·6 months; hazard ratio [HR] 0·78; 95% CI 0·63-0·97; p=0·025). Common treatment-related adverse events (>30%) in the atezolizumab and control groups were blood creatinine phosphokinase increased (51·3% vs 44·8%), diarrhoea (42·2% vs 46·6%), rash (40·9%, both groups), arthralgia (39·1% vs 28·1%), pyrexia (38·7% vs 26·0%), alanine aminotransferase increased (33·9% vs 22·8%), and lipase increased (32·2% vs 27·4%); 13% of patients in the atezolizumab group and 16% in the control group stopped all treatment because of adverse events.Interpretation The addition of atezolizumab to targeted therapy with vemurafenib and cobimetinib was safe and tolerable and significantly increased progression-free survival in patients with BRAF V600 mutation-positive advanced melanoma.Funding F Hoffmann-La Roche and Genentech.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)30934-x

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Cited by

See all 699

Metadata

Authors
Gutzmer, R., Stroyakovskiy, D., Gogas, H., Robert, C., Lewis, K., Protsenko, S., Pereira, R. P., Eigentler, T., Rutkowski, P., Demidov, L., Manikhas, G. M., Yan, Y., Huang, K.-C., Uyei, A., McNally, V., McArthur, G. A., & Ascierto, P. A.
Affiliations
  • Medizinische Hochschule Hannover (DE)
  • Moscow City Oncology Hospital №62 (RU)
  • National and Kapodistrian University of Athens (GR)
  • Université Paris-Saclay (FR)
  • University of Colorado Cancer Center (US)
  • Hospital de Clínicas de Porto Alegre (BR)
  • Universitätsklinikum Tübingen (DE)
  • The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
  • Genentech (US)
  • Roche (United Kingdom) (GB)
  • Peter MacCallum Cancer Centre (AU)
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Corresponding author
Gutzmer, Ralf
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-06
Volume
395
Issue
10240
Pages
1835-1844
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3034459487
Cited by
663
References
28
Citations by year
2026: 54 · 2025: 59 · 2024: 110 · 2023: 116 · 2022: 151 · 2021: 136 · 2020: 35
FWCI
35.69
Type
journal article
Language
en
Update notices
erratum (2020-08-15)
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
atezolizumab, vemurafenib, cobimetinib, BRAF V600 mutation, advanced melanoma, immune checkpoint inhibitors, combination therapy, first-line therapy, progression-free survival, PD-L1 blockade, MEK inhibition, BRAF inhibition, treatment-related adverse events, immunotherapy safety, metastatic melanoma
MeSH terms
Vemurafenib, Progression-Free Survival, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Azetidines, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasm Staging, Piperidines, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)30934-x
The paper
Gutzmer, R., Stroyakovskiy, D., Gogas, H., Robert, C., Lewis, K., Protsenko, S., Pereira, R. P., Eigentler, T., Rutkowski, P., Demidov, L., Manikhas, G. M., Yan, Y., Huang, K.-C., Uyei, A., McNally, V., McArthur, G. A., & Ascierto, P. A. (2020). Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)30934-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.